Arbutus Biopharma
ABUS
55 hedge funds and large institutions have $212M invested in Arbutus Biopharma in 2015 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 18 closing their positions.
62% more call options, than puts
Call options by funds: $1.4M | Put options by funds: $864K
21% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 14
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 63 → 55 (-8)
39% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 18
52% less capital invested
Capital invested by funds: $442M → $212M (-$230M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$6.72M |
| 2 |
HM
HealthCor Management
New York
|
+$3.77M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$3.72M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.52M |
| 5 |
Axa
Paris,
France
|
+$3.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRC
Blue Ridge Capital
New York
|
-$20.2M |
| 2 |
RIM
RS Investment Management
San Francisco,
California
|
-$11.5M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$9.2M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$5.1M |
| 5 |
AC
Ascend Capital
Orinda,
California
|
-$4.39M |
ABUS Hedge Fund Activity: Q3 2015 in Review
55 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2015, worth a combined $212M — down 52% from $442M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ABUS and 11 opened new positions — a net loss of 7 holders — while 14 trimmed existing stakes and 17 added.
The largest buyer was Primecap Management, adding an estimated $6.72M. The largest seller was Blue Ridge Capital, exiting entirely with an estimated $20.2M sold.
- 55 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2015, down from 63 in Q2 2015.
- Funds reported $212M of Arbutus Biopharma stock for Q3 2015, down 52% quarter-over-quarter.
- 11 funds opened new Arbutus Biopharma positions in Q3 2015 and 18 closed out, a net change of -7 holders.
- The largest Arbutus Biopharma buyer in Q3 2015 was Primecap Management, an estimated $6.72M added.
- The largest Arbutus Biopharma seller in Q3 2015 was Blue Ridge Capital, an estimated $20.2M sold.
Based on aggregated 13F filings for Q3 2015.